Options Volatility and Implied Earnings Moves Today, May 13, 2024
TipRanks (Mon, 13-May 7:05 AM ET)
Options Volatility and Implied Earnings Moves This Week, May 13 – May 16, 2024
TipRanks (Mon, 13-May 7:00 AM ET)
Notable earnings after Monday's close
Seeking Alpha News (Sun, 12-May 5:35 PM ET)
Cara Therapeutics Q1 2024 Earnings Preview
Seeking Alpha News (Sun, 12-May 5:35 PM ET)
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
Globe Newswire (Mon, 6-May 7:00 AM ET)
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Globe Newswire (Tue, 2-Apr 7:00 AM ET)
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
Globe Newswire (Thu, 7-Mar 7:00 AM ET)
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
Globe Newswire (Mon, 4-Mar 4:01 PM ET)
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Cara Therapeutics trades on the NASDAQ stock market under the symbol CARA.
As of May 13, 2024, CARA stock price climbed to $0.74 with 177,249 million shares trading.
CARA has a beta of 2.61, meaning it tends to be more sensitive to market movements. CARA has a correlation of 0.09 to the broad based SPY ETF.
CARA has a market cap of $40.45 million. This is considered a Sub-Micro Cap stock.
Last quarter Cara Therapeutics reported $3 million in Revenue and -$.59 earnings per share. This fell short of revenue expectation by $-6 million and missed earnings estimates by -$.18.
In the last 3 years, CARA stock traded as high as $18.93 and as low as $.50.
The top ETF exchange traded funds that CARA belongs to (by Net Assets): VTI, IWM, VXF, IWN, SCHA.
CARA stock has underperformed the market in the last year with a return of -82.2%, while SPY returned +27.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CARA shares. However, CARA has outperformed the market in the last 3 month and 2 week periods, returning +30.8% and +8.1%, while SPY returned +4.3% and +2.5%, respectively. This indicates CARA has been having a stronger performance recently.
CARA support price is $.67 and resistance is $.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CARA stock will trade within this expected range on the day.